Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Trimeris down on Fuzeon sales

TRMS slipped $2.45 to $46.58 on 2 million shares on Wednesday after

Read the full 124 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE